Snyder Emily M, Krishna Gopika, Zapata Lauren B, Nguyen Antoinette T, Whiteman Maura K, Curtis Kathryn M
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States; Oak Ridge Institute for Science and Education, Oak Ridge, TN, United States.
Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA, United States; Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY, United States.
Contraception. 2025 May 22:110971. doi: 10.1016/j.contraception.2025.110971.
To systematically review evidence on whether medications with smooth muscle relaxant properties improve patient and provider outcomes for intrauterine device (IUD) placement.
We searched multiple databases through August 2022 for randomized clinical trials assessing smooth muscle relaxants for IUD placement. Primary outcomes were pain experienced with IUD placement, provider ease of placement, need for adjunctive placement measures, placement success, patient satisfaction with procedure, medication side effects occurring before clinic discharge, and adverse events occurring before clinic discharge. We extracted data from included articles, assessed risk of bias for each trial, narratively summarized results, and determined certainty of evidence for all outcomes.
Five placebo-controlled trials met inclusion criteria; four trials had low risk of bias and one had moderate risk. Two trials of topical nitroprusside gel or nitroglycerin ointment found no differences in patient pain, provider ease of placement, patient satisfaction, placement success, side effects, or adverse events. One trial suggested that drotaverine plus mefenamic acid reduced patient pain but did not improve placement success. Two trials suggested that isonicotinic acid hydrazide reduced patient pain, improved provider ease of placement and patient satisfaction, reduced need for analgesia and for cervical dilation (in one trial) and did not increase side effects; neither trial reported improved placement success.
Evidence on smooth muscle relaxants for IUD placement remains sparse with inconsistent findings across specific medications. Certainty of evidence for all outcomes was low for topical nitroprusside gel and nitroglycerin ointment, very low for drotaverine plus mefenamic acid, and mostly high for isonicotinic acid hydrazide.
Before IUD placement, healthcare providers can counsel patients on the potential for pain during placement and options for pain management. However, more evidence is needed on specific smooth muscle relaxants to determine their effectiveness as an intervention for IUD placement.
系统评价具有平滑肌松弛特性的药物是否能改善宫内节育器(IUD)放置的患者和医护人员相关结局。
我们检索了多个数据库,截至2022年8月,查找评估用于IUD放置的平滑肌松弛剂的随机临床试验。主要结局包括IUD放置时的疼痛、医护人员放置的难易程度、辅助放置措施的需求、放置成功率、患者对手术的满意度、出院前出现的药物副作用以及出院前发生的不良事件。我们从纳入的文章中提取数据,评估每个试验的偏倚风险,叙述性总结结果,并确定所有结局的证据确定性。
五项安慰剂对照试验符合纳入标准;四项试验偏倚风险低,一项试验偏倚风险中等。两项关于局部用硝普钠凝胶或硝酸甘油软膏的试验发现,在患者疼痛、医护人员放置的难易程度、患者满意度、放置成功率、副作用或不良事件方面没有差异。一项试验表明,屈他维林加甲芬那酸可减轻患者疼痛,但未提高放置成功率。两项试验表明,异烟肼可减轻患者疼痛,提高医护人员放置的难易程度和患者满意度,减少镇痛需求和宫颈扩张需求(一项试验中),且未增加副作用;两项试验均未报告放置成功率提高。
关于用于IUD放置的平滑肌松弛剂的证据仍然稀少,不同特定药物的研究结果不一致。局部用硝普钠凝胶和硝酸甘油软膏所有结局的证据确定性低,屈他维林加甲芬那酸的证据确定性非常低,异烟肼的证据确定性大多为高。
在放置IUD之前,医疗保健提供者可以就放置过程中疼痛的可能性以及疼痛管理选项向患者提供咨询。然而,需要更多关于特定平滑肌松弛剂的证据,以确定它们作为IUD放置干预措施的有效性。